Pharmaceuticals

Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021

* Two South Korean radiologists share benefits and feedback of using AI products for chest x-rays and mammograms in an actual patient care * Company expects to deliver the diagnostic value of AI and expand its implementation across clinical sites in theAsia-Pacific region SEOUL, June 23, 2021...

2021-06-23 10:28 2954

Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma

SAN FRANCISCO and SUZHOU, China, June 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-06-23 09:16 20402

Global Water Scarcity and Hospitalization Rates Stimulate the Polymeric Membranes Market

The demand for water treatment membranes and medical membranes will drive the global market, says Frost & Sullivan SANTA CLARA, Calif., June 23, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis of the global polymeric membranes market finds that the drive to achieve a circular economy and...

2021-06-23 00:14 1959

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform

ST. CHARLES, Mo., June 22, 2021 /PRNewswire/ -- Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (EUFI.PA) company, and ImmunoPrecise Antibodies (Nasdaq:IPA), the market leader in full-service therapeutic discovery and deve...

2021-06-22 20:28 3855

Alfasigma acquires the European license for bentracimab from PhaseBio

BOLOGNA, Italy, 22 giugno 2021 /PRNewswire/ -- Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), for the commercialization of bentracimab in 49 countries acrossEurope and other key markets. PhaseBio is a biopharmaceutical company focu...

2021-06-22 14:45 2266

Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

SHANGHAI, June 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient inEurope in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being developed for ...

2021-06-22 13:15 1387

2021 ASCO - AnchorDx Unveils Robust Validation Result of Multi-cancer Screening Technology AURORA

GUANGZHOU, China, June 21, 2021 /PRNewswire/ -- At this year's American Society of Clinical Oncology (ASCO) Annual Meeting 2021 (June 4-8), AnchorDx, a world-leading developer of cancer screening and early detection solutions, unveiled further validation results on the generalization performance ...

2021-06-21 23:19 537

I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board

SHANGHAI and GAITHERSBURG, Md., June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment ofAndrew Zhu, MD, PhD, to the Company's ...

2021-06-21 20:00 7556

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral o...

2021-06-21 19:00 7295

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors

HONG KONG, June 21, 2021 /PRNewswire/ --  HUTCHMED (China) Limited ("HUTCHMED ") (Nasdaq/AIM: HCM) today announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration ofChina ("NMPA") for the treatment of adv...

2021-06-21 15:15 3988

CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy

SUZHOU, China, June 21, 2021 /PRNewswire/ -- GAVRETO® (pralsetinib), a precision therapy discovered by CStone Pharmaceuticals' partner Blueprint Medicines, had the first batch of prescriptions issued at Guangdong Province People's Hospital and around 100 other hospitals acrossChina. GAVRETO is al...

2021-06-21 13:06 2952

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-06-21 08:00 6251

CARsgen Therapeutics officially listing on HKEX

HONG KONG, June 19, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (the "Company", stock code: 2171.HK) today announced that the Company's Shares have been traded on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code "2171.HK".

2021-06-19 02:57 9284

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus. ...

2021-06-18 14:16 14504

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus. ...

2021-06-18 14:04 14296

Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)

HONG KONG, June 18, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®#  (tenofovir alafenamide 25 mg, TAF) from tenofovir disoproxil fumarate (T...

2021-06-18 10:00 2205

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment

BEIJING and SHANGHAI and BOSTON, June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced that the first two patients have been dosed in the Phase 1/2a clinical trial ofSHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respe...

2021-06-18 08:31 3518

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-06-18 08:00 3219

Envirotainer Announces Cathay Pacific as First Asian carrier for the recently released Releye® RLP container

STOCKHOLM, June 17, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that Cathay Pacific has approved the Envirotainer Releye® RLP for carriage on its fleet of aircraft. Cathay Pacific can now off...

2021-06-17 19:49 1516

Elekta radiotherapy system designed for changing cancer landscape now available for U.S. patients

ATLANTA, June 17, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its Elekta Harmony* radiation therapy system recently received U.S. FDA 510(k) clearance, paving the way for U.S. clinics to harness the system to treat a comprehensive range of indications using the latest radiotherap...

2021-06-17 14:38 15352
1 ... 237238239240241242243 ... 314

Week's Top Stories